Adanma Anji Ayanambakkam Attanathi
Hematology & Oncology · Oklahoma City, OKNPI 1265813513
Payments from drug & device makers
Across 186 payments — averaging $10,217 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$1.8M
- Seagen Inc.$66K
- Johnson & Johnson$6K
- Janssen Research & Development, LLC$5K
- AVEO Pharmaceuticals, Inc.$2K
- Exelixis Inc.$600
- plus $2K from 19 others
Across 3 payments — averaging $533.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$2K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 70 | $1,818,512 |
| Seagen Inc. | 8 | $66,294 |
| Johnson & Johnson | 7 | $6,049 |
| Janssen Research & Development, LLC | 1 | $5,250 |
| AVEO Pharmaceuticals, Inc. | 1 | $1,815 |
| Exelixis Inc. | 1 | $600 |
| Bristol Myers Squibb | 19 | $258 |
| Astellas Pharma US Inc | 8 | $191 |
| AstraZeneca | 8 | $168 |
| Merck | 7 | $162 |
| E.r. Squibb & Sons, L.L.C. | 8 | $153 |
| Bayer | 11 | $144 |
| Caris MPI, Inc. | 1 | $133 |
| Novartis | 5 | $117 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $108 |
| Lilly USA, LLC | 7 | $102 |
| Incyte Corporation | 5 | $80 |
| Agios Pharmaceuticals, Inc. | 4 | $60 |
| Rigel Pharmaceuticals, Inc. | 3 | $56 |
| Amgen | 2 | $50 |
| Jazz Pharmaceuticals Inc. | 3 | $49 |
| Gilead | 1 | $21 |
| Urogen Pharma, Inc. | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$1,900,416 in reported general payments places this provider in the 95th percentile of 118 hematology & oncology providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Oklahoma City
- Adam AschOklahoma City$2M
- Hassan HatoumOklahoma City$1.4M
- Abdul Rafeh NaqashOklahoma City$1.1M
- Sami IbrahimiOklahoma City$1M
- Carrie YuenOklahoma City$564K
- David LamOklahoma City$445K
- Romeo MandanasOklahoma City$419K
- Carla KurkjianOklahoma City$310K
- Sonia VargheseOklahoma City$295K
- Mohammad RazaqOklahoma City$267K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.